<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998619</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2016-01325</org_study_id>
    <nct_id>NCT02998619</nct_id>
  </id_info>
  <brief_title>Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis</brief_title>
  <official_title>Retrospektive Analyse Der Radiotherapie Des Pelvinen Lymphabflusses Beim Lokalisierten Prostatakarzinom Vom Hochrisikotyp Anhand Der Klinikdatenbank 2010-2016</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Graubuenden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Graubuenden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men with high risk prostate cancer who underwent radiotherapy of the prostate/seminal
      vesicles or underwent postoperative radiotherapy including pelvic lymph nodes between 2010
      and 2016 are analyzed retrospectively. The aims are to estimate progression-free survival as
      well as toxicity according to CTCAE v4.03.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collection of data and retrospective analysis of patients with high risk prostate cancer
      treated with radiotherapy to pelvic lymph nodes.

      What influence has irradiation of pelvic lymph nodes on patients with high risk prostate
      cancer in terms of progression free survival and toxicity. How does this influence side
      effects with respect to gastrointestinal (proctitis, abdominal pain, diarrhea) and
      genitourinary (cystitis, urinary disorders) toxicities (CTCAE v4.03)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (CTCAE v4.03)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Neoplasms Benign</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Lymph Node Disease</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <description>Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective analysis of men irradiated for high risk prostate cancer including pelvic
        lymph nodes (L5/S1)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with high risk prostate cancer treated with radiotherapy to prostate/seminal
             vesicles or postoperative radiotherapy and pelvic lymph nodes at the Kantonssptial
             Graubuenden, Department of Radiation Oncology between 2010 and 2016

        Exclusion Criteria:

          -  Men with prostate cancer other than high risk disease and no radiotherapy to pelvic
             lymph nodes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel R Zwahlen, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Graubuenden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel R Zwahlen, MD, MBA</last_name>
    <phone>+41 81 256 64 95</phone>
    <email>daniel.zwahlen@ksgr.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Oehler, MD, MBA</last_name>
    <phone>+41 81 256 64 95</phone>
    <email>christoph.oehler@ksgr.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel R Zwahlen, MD, MBA</last_name>
      <phone>+41 81 256 64 95</phone>
      <email>daniel.zwahlen@ksgr.ch</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Oehler, MD, MBA</last_name>
      <phone>+41 81 256 64 95</phone>
      <email>christoph.oehler@ksgr.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Giulia Gantner, BMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

